caprotec bioanalytics Announces Commercial Launch of Three New caproKits™ For Applications in Functional Proteomics and Drug Development
Berlin, Germany and Burlington, MA, September 30, 2010 – caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits™, enabling the discovery, identification and characterization of proteins for applications in functional proteomics and drug development.
The three new kits are the Dasatinib caproKit, the C2‐cAMP caproKit and the Biotin Capping Kit. Together, these new kits increase the number of commercially available caproKits to a total of 10.
The company’s caproKits are based on the proprietary Capture Compound Mass Spectrometry (CCMS) technology, a novel and direct way to investigate small molecule–protein interactions resulting in a significant functional reduction of proteome complexity. Capture Compounds™ enable the direct isolation and identification of defined protein classes, including membrane proteins, out of complex biological samples.
The new and existing caproKits target different areas of research ranging from signal transduction to epigenetics and proteases. The Dasatinib and C2‐cAMP caproKits are the newest additions to the company’s signal transduction product line. The Biotin Capping Kit is used to improve analytical performance by decreasing background noise when study samples contain a high amount of naturally biotinmodified proteins. caproKits are versatile reagents and can be broadly used across different species and sources of sample material. Additional caproKits for applications in other research areas are under development and will be released in the coming months.
“We are pleased to now offer a broad suite of products specifically for kinases and nucleotide binding proteins, both being of paramount importance in signal transduction and drug discovery research,” stated Dr. Hubert Köster, CEO of caprotec bioanalytics. “Our new caproKits are innovative and effective chemical proteomics tools for researchers in need of a solution for targeted reduction of sample complexity.”
About caprotec bioanalytics GmbH
caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri‐functional molecules called Capture Compounds™. They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry or gel electrophoresis and Western blotting. Providing a stateof‐ the‐art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.